JNNP podcast

BMJ Group

JNNP's ambition is to publish the most ground-breaking and cutting-edge research from around the world. Encompassing the entire genre of neurological sciences, our focus is on the common disorders (stroke, multiple sclerosis, Parkinson's disease, epilepsy, peripheral neuropathy, subarachnoid haemorrhage and neuropsychiatry), but with a keen interest in the Gordian knots that present themselves in the field, such as ALS.

* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

All Episodes

Prof Michael Barnett, Director Sydney Neuroimaging Analysis Centre and Professor of Neurology, University of Sydney, joins JNNP's Podcast Editor, Colin Mahoney, to discuss how the use of Alemtuzumab may have longer-term impacts on improving one of the most commonly involved neurological pathways, the visual system, in multiple sclerosis (MS). Prof Barnett discusses his team's results after following up patients with highly active MS for 24 months, using multifocal visual evoked potentials and advanced neuroimaging. He also talks about what this means for future remyelination strategies. Related paper: https://jnnp.bmj.com/content/92/12/1319

Nov 17

20 min 1 sec

A/Prof Jan Baker, Speech Pathologist, Flinders University and UTS. Dr Laura McWhirter, University of Edinburgh joins editor Colin Mahoney to discuss the first comprehensive guidelines developed to assist speech and language professionals in the management of functional communication, voice, swallow and cough disorders. As part of a global team they have developed a set of clinically focused guidelines in the recognition and management of theses disorders and discuss the highlights on the Podcast. https://jnnp.bmj.com/content/92/10/1112

Sep 27

23 min 8 sec

Mark Goh and Shu-Ling Chong, Duke-NUS Medical School and KK Women's and Children's Hospital, Singapore joins editor Colin Mahoney to discuss their systematic review and meta-analysis spanning 6000 articles dealing with neurocognitive outcomes following traumatic brain injury (TBI) in children. They highlight how dose of TBI impacts executive function and memory with potentially long term impacts. https://jnnp.bmj.com/content/92/8/847

Aug 31

9 min 54 sec

Cerebral Microbleeds are increasingly recognised due to increased availability of neuroimaging and are known to be associated with increased risk of stroke, in particular intracerebral haemorrhage. In this podcast Dr Laurent Puy joins editor Colin Mahoney to discuss their histopathology, epidemiology and impact on clinical decision making in a state-of-the-art review published in June's JNNP. https://jnnp.bmj.com/content/92/6/598

Jul 5

10 min 23 sec

Over the last ten years, huge progress has been made in the common but often poorly understood condition of motor Functional Neurological Disorder (mFND). In this podcast, Dr W. Curt La France, Jr., Professor of Neurology and Psychiatry, Brown University, USA, joins editor Colin Mahoney to discuss diagnosis, insights on disease mechanisms, and emerging therapeutic approaches. They also highlight the stigma associated with mFND and ways to improve outcomes for patients. Read the paper on the JNNP website and the journal's June issue: https://jnnp.bmj.com/content/92/6/668

Jun 25

9 min 51 sec

The Oxford Astra Zeneca vaccine has been associated with a rare complication of cerebral venous sinus thrombosis. Dr Colin Mahoney, JNNP Podcast Editor, interviews Prof David Werring, Professor of Clinical Neurology, UCL Queen Square Institute of Neurology, UK, about the new evidence which supports an association between vaccination and more common large vessel arterial stroke. They also discuss several cases, including treatment, and emerging biological evidence relating to causation. Read the paper "Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopaenia", on the JNNP website: https://jnnp.bmj.com/content/early/2021/05/20/jnnp-2021-326984. Related editorial paper: https://jnnp.bmj.com/content/early/2021/05/20/jnnp-2021-327057

Jun 3

13 min 14 sec

Prof Alaisdair Coles and Dr Nick Cunniffe, The University of Cambridge joins editor Colin Mahoney to discuss: The work carried out by a team of researchers alongside the MS Society in the United Kingdom. The authors discuss the process of identifying therapies to repurpose in future MS trials and why they think this drugs may work. https://jnnp.bmj.com/content/92/3/295

Mar 2

8 min 48 sec

Rick Thurbon, patient editorial board member. Prof Matthew Kiernan and A/Prof Susanna Park from The University of Sydney joins editor Colin Mahoney to discuss: In 1960 a landmark paper was published by Hyam Isaac on a syndrome of continuous muscle activity. The spectrum of Isaac's Syndrome has broadly widened since then and we reflect on this with patients and experts in this field. https://jnnp.bmj.com/content/91/12/1243

Nov 2020

11 min 55 sec

Jonathan Tay joins our podcast editor Colin Mahoney to discuss the findings from two large cohort studies of cerebral small vessel disease, highlighting the fact that apathy can predict future dementia risk in these patients. https://jnnp.bmj.com/content/91/9/953

Sep 2020

8 min 6 sec

Dr Laura Mc Whirter joins our podcast editor Colin Mahoney to discuss her recent systematic review of performance validity tests used across a range of neurological and psychiatric disorders. Are these tests useful and which conditions are the most likely to be helpful in. Join us to find out. https://jnnp.bmj.com/content/91/9/945

Sep 2020

12 min 29 sec

Prof Joseph Jankovic, Distinguished Chair in Movement Disorders, Baylor College of Medicine joins Podcast editor Colin Mahoney. Prof Jankovic provides a historical look back on the key developments in our understanding of the causes of Parkinson's disease and key treatments. https://jnnp.bmj.com/content/91/8/795

Aug 2020

24 min 1 sec

Dr Timothy Nicholson joins Podcast editor Colin Mahoney to discuss their recent systematic review of outcome measures used across the spectrum of functional neurological disorders. As well as identifying key domains for assessment he also discusses the challenges and future directions in developing more rigorous validated outcome measures for these increasingly recognised disorders. https://jnnp.bmj.com/content/91/6/638

Jul 2020

12 min 40 sec

Dr Christian Lobue, lead author joins Podcast Editor Colin Mahoney to discuss his original research which examines the clinical, neuropsychological and neuropsychiatric features of those with confirmed chronic traumatic encephalopathy (CTE) at autopsy. He compares the features with patients with CTE and those with Alzheimer's disease. https://jnnp.bmj.com/content/91/6/586

Jun 2020

16 min 22 sec

Prof John O'Brien (University of Cambridge) and Dr Dominic Ffytche (Kings College London) join Dr Colin Mahoney (Podcast Editor) Visual hallucinations have complex origins and can have significant impact on patients. The recent UK based SHAPED consortium has aimed to design a common framework for assessment, management and research in this area. John O'Brien and Dominic Ffytche discuss disorders which cause visual hallucinations as well as their pathobiology and management in this Podcast: https://jnnp.bmj.com/content/91/5/512

May 2020

22 min 8 sec

Prof Martin Turner, University of Oxford, joins Dr Colin Mahoney to discuss the newest consensus clinical criteria to aid in the diagnosis of Primary Lateral Sclerosis. This will enable neurologists to make the diagnosis sooner and will be important in the design of future treatment trials. https://jnnp.bmj.com/content/91/4/373

May 2020

14 min 3 sec

Dr Hadi Manji joins Colin Mahoney to discuss the recent paper by Liu and colleagues as well as providing a commentary on how COVID-19 may impact the nervous system and steps to mitigate this. He also discusses the impact of COVID-19 in delivering care at the National Hospital for Neurology and Neurosurgery, located in one of the new epicentres for this disease. https://jnnp.bmj.com/content/early/2020/04/20/jnnp-2020-323414

May 2020

15 min 18 sec

Prof Andrew Lees, Professor of Neurology National Hospital for Neurology and Neurosurgery. Colin Mahoney JNNP Podcast Editor As part of our 2020 Vision centenary Prof Andrew Lees reviews how Lithium (eventually) became established in the treatment of psychiatric illness, reviewing the 1954 paper by Schou and colleagues. https://jnnp.bmj.com/content/jnnp/91/4/335.full

Apr 2020

20 min 48 sec

Colin Mahoney, JNNP Podcast editor, is joined by Dr Jonathan Rohrer, MRC Clinician Scientist, Dementia Research Centre, UCL Institute of Neurology. Carolin Heller, Dementia Research Centre and UK Dementia Research Institute. to discuss how increased levels of GFAP may be used to detect advancing neurodegeneration and clinical change in those with Progranulin associated Frontotemporal Dementia. https://jnnp.bmj.com/content/91/3/263

Mar 2020

13 min 40 sec

Prof Bruce Taylor, Menzies Institute for Medical Research, University of Tasmania and Dr Colin Mahoney JNNP Podcast editor Prof Bruce Taylor joins our podcast editor Colin Mahoney to discuss recent advances in the diagnosis and management of multifactorial neuropathy. They discuss the current state-of-the art on pathogenesis, new diagnostic approaches and management. https://jnnp.bmj.com/content/91/2/140.info

Mar 2020

14 min 12 sec

As part of our 2020 Vision Series reviewing the most seminal papers in JNNP's past Prof Niall Quinn, joins Colin Mahoney to discuss his 1989 paper which provided the first clinical criteria for MSA. He discusses how the last 30 years of science has shaped this original work, and he also shares his experiences of his mentor Prof David Marsden who previously served as the editor of JNNP. https://jnnp.bmj.com/content/91/1/3

Feb 2020

13 min 48 sec

Sharon Roman, a patient advocate who suffers with Multiple Sclerosis, discusses the complexities of measures of disease activity and employment in MS. https://jnnp.bmj.com/content/91/1/5

Jan 2020

12 min 33 sec

Dr Susanna Park joins Colin Mahoney to discuss neurophysiological, imaging and other methods to study an increasingly recognised problem of chemotherapy induced peripheral neurotoxicity. Dr Park outlines the pathology and current techniques to diagnose and monitor this problem, and outline new areas of research as well as recommendations from the Toxic Neuropathy Consortium to improve clinical care and research in this area. https://jnnp.bmj.com/content/90/12/1361

Dec 2019

9 min 3 sec

Dr Oliver Robinson joins Colin Mahoney to discuss the neural circuitry of anxiety, outlining our current understanding the anatomical basis for anxiety, as well as paradigms used to explore the shared circuits which lead to pathological levels of anxiety. Dr Robinson also outlines the future research goals in this important area. https://jnnp.bmj.com/content/90/12/1353

Nov 2019

18 min 45 sec

Dr Neil Graham and Prof David Sharp, from Imperial College London, discuss the interaction between traumatic brain injury and dementia. They outline the epidemiology, pathogenesis and emerging biomarkers in an area which is seeing increased attention. Read the full paper here: https://jnnp.bmj.com/content/90/11/1221.long

Oct 2019

20 min 19 sec

Dr Robert Simpson (University of Glasgow, UK) discusses the merits and limitations of mindfullness based treatments for mental well-being in Multiple Sclerosis (MS). Read the full paper here: https://jnnp.bmj.com/content/90/9/1051

Sep 2019

17 min 13 sec

Professor Helmar Lehmann (University Hospital of Cologne) provides an update on Chronic inflammatory demyelinating polyneuropathy (CIDP) and discusses recent advances in diagnosis and treatment. Read the full paper here: https://jnnp.bmj.com/content/90/9/981.long

Sep 2019

9 min 57 sec

Elizabeth Highton (podcast editor) is joined by Professor Alfonso Fasano (Toronto Western Hospital, Ontario, Canada) to discuss the overlapping phenomenology and diagnostic challenges in movement disorders and seizures. Read the paper here: https://jnnp.bmj.com/content/90/8/920.long

Aug 2019

18 min 8 sec

Dr. David Perez (Massachusetts General Hospital, USA) speaks with JNNP Podcast Editor, Elizabeth Highton about stepwise functional connectivity, a novel brain imaging technique, and how it might help us better understand the biology of functional neurological disorders. Read this month's Patient's Choice article here: https://jnnp.bmj.com/content/90/8/929

Jul 2019

12 min 57 sec

Dr. Susannah Pick (King’s College London, UK) discusses emotional processing in functional neurological disorder, and how further understand of emotional processing deficits may help contribute to a unified explanatory model for FND.

Jun 2019

12 min 12 sec

Dr Shelly Coe (Oxford Brookes University, Oxford) discusses a new randomized control trial looking at the use of cocoa for management of fatigue in multiple sclerosis. Read the full paper here: https://jnnp.bmj.com/content/90/5/507

May 2019

6 min 59 sec

JNNP Associate Editor, Professor Nick Ward (Queens Square, London) tells us all about the Queen Square Upper Limb Neurorehabilitation programme, and specifically, what clinical gains in chronic stroke patients were observed after high intensity neurorehabilitation. Read the full paper here: https://jnnp.bmj.com/content/90/5/498

May 2019

12 min 47 sec

The JNNP recently launched the patient editorial board in an effort to drive more meaningful patient outcomes. One of our newly appointment board members, Sharon Roman (Vancouver Canada) discusses why she believes the patient perspective leads to better healthcare and what the patient partnership looks like at the JNNP. Read Sharon’s editorial here: https://jnnp.bmj.com/content/jnnp/90/4/371.full.pdf

Apr 2019

12 min 43 sec

A special edition podcast - based on an essay discussing the value of medical conferences and whether it is time to consider what is gained from these events, and for whom. Emeritus Professor Michael Swash (The Royal London Hospital and Barts and the London School of Medicine) joins Elizabeth Highton to discuss the merits of the medical congress. Read the commentary here: https://jnnp.bmj.com/content/early/2018/10/18/jnnp-2018-319248

Apr 2019

9 min 30 sec

Associate Professor Tomas Kalincik (University of Melbourne, Australia) discusses oral immunotherapies, and what we know about the effects of these treatments on patient relapse and disability. Read the full paper here: https://jnnp.bmj.com/content/early/2019/01/12/jnnp-2018-319831

Mar 2019

12 min 12 sec

Editor’s Choice: Associate Professor Dr Mario Masellis (University of Toronto) and Assistant Professor Philippe Desmarais (University of Montreal) discuss the complexities of designing trials in frontotemporal dementia (FTD) and how precision medicine might help disentangle this Gordian knot in the future. Read the full paper here: https://jnnp.bmj.com/content/jnnp/early/2018/11/01/jnnp-2018-318603.full.pdf

Mar 2019

13 min 5 sec

Professor Ammar Al-Chalabi (King’s College London, London, UK) joins Elizabeth Highton (podcast editor) to discuss motor neurone disease, also known as amyotrophic lateral sclerosis or ALS, a rapidly progressive illness resulting from the degeneration of both upper and lower motor neurons. Studies have shown that age of onset is younger in people with a family history – but it this due to a heightened knowledge of the disease or due to genetics lowering the age of onset? Read the full paper here: https://jnnp.bmj.com/content/jnnp/90/3/268.

Mar 2019

9 min 49 sec

We have a good understanding of our risk of developing cancer or heart disease – but what do we know about the risk of developing a common neurological disorder in later-life? Dr. Silvan Licher (Department of Epidemiology, University Medical Center Rotterdam, Netherlands) discusses the lifetime risk of developing dementia, stroke, and Parkinson’s disease, and how we need to better prioritise preventive interventions. Read the full paper here: https://jnnp.bmj.com/content/jnnp/90/2/148.full.pdf

Feb 2019

6 min 16 sec

Dr. Michael van Es (University Medical Center Utrecht, Netherlands) examines whether cognitive and behavioural changes can be seen across the motor neurone disease spectrum, and how this helps inform our understanding of these as multidimensional diseases. Read the editorial commentary by Professor Martin Turner here: https://jnnp.bmj.com/content/90/2/122

Feb 2019

8 min 57 sec

Do statins increase the risk of intracerebral haemorrhage (ICH) in patients with a previous stroke? Professor David Werring (Stroke Research Centre, UCL Institute Of Neurology, Queen Square, London, UK) joins Elizabeth Highton (JNNP podcast editor) for the first JNNP podcast of 2019. Read the full paper here: https://jnnp.bmj.com/content/90/1/75

Jan 2019

12 min 2 sec

Elizabeth Highton (podcast editor) hosts the final JNNP podcast for 2018, an episode on functional improvement after stroke (Dr. Aravind Ganesh, University of Oxford, UK- https://jnnp.bmj.com/content/89/12/1301) and cognitive impairment in functional neurological disorders (Dr. Jeremy Isaacs (St George’s University and Hospital, London, UK - https://jnnp.bmj.com/content/89/12/1308).

Dec 2018

28 min 56 sec

Professor Mark Humphries (University of Nottingham, UK) discusses how computational modelling could be a crucial tool in untangling the complexities of diseases like Parkinson’s disease. Can this type of modelling help us understand causes, and eventually lead to treatment options? Read the full paper here: https://jnnp.bmj.com/content/early/2018/04/17/jnnp-2017-315922.long

Oct 2018

11 min 51 sec

In collaboration with many different specialists, professions and patient representatives, Mollan et al (2018) have developed the first ever guidelines for the investigation and management of idiopathic intracranial hypertension (IIH). Senior author, Dr Alexandra Sinclair (University of Birmingham) discusses these with the JNNP podcast editor, Elizabeth Highton. Read the full guidelines here: https://jnnp.bmj.com/content/89/10/1088 Access the Practical Neurology infographic summary here: https://pn.bmj.com/content/early/2018/08/28/practneurol-2018-002009

Oct 2018

14 min 54 sec

Elizabeth Highton (JNNP Podcast Editor) speaks with Dr. Michelle Farrar (University of New South Wales) discussing nusinersen, the first disease-modifying therapy for spinal muscular atrophy type 1 (SMA). https://jnnp.bmj.com/content/89/9/937

Aug 2018

10 min 19 sec

Dr. Carlo Rinaldi (University of Oxford) discusses how the traditional view of Kennedy’s disease is evolving, to extend beyond pure motor symptoms. What non-motor features may be present in Kennedy's, and crucially how do they impact on patient's care and management? Read the full paper here: https://jnnp.bmj.com/content/89/8/808. Helle Stangeland and Vaughan Bell join us to discuss a much overlooked clinical syndrome in stroke: poststroke psychosis. Just how often does it occur and how can it be treated? Read their systematic review here: https://jnnp.bmj.com/content/89/8/879.

Aug 2018

28 min 46 sec

Around 20-30% of patients with epilepsy can demonstrate resistance to commonly used medications. Cannabidiol (CBD) is a compound found in cannabis, which can be used for the treatment of epilepsy, shown to actively modulate seizure activity. Dr Emily Stockings (University of New South Wales in Sydney, Australia ) outlines how CBD can be helpful for patients with drug-resistant epilepsy. Read the full paper here: http://jnnp.bmj.com/content/89/7/741.long Dr Georg Kaji (Kantonsspital, St.Gallen, Switzerland) provides a historical overview of surgical techniques and incisionless interventions for tremor – how have interventions changed over time? Read the full paper here: http://jnnp.bmj.com/content/89/7/727.long

Jul 2018

23 min 27 sec

Is the mesial temporal lobe the seat of psychosis in epilepsy? James Allebone (University of Melbourne, Australia) discusses what neuroimaging can tell us about psychosis in epilepsy. Read the paper here: http://jnnp.bmj.com/content/89/6/611. Patients with epilepsy are often not permitted to drive, but can this change after surgery? Professor John Duncan (University College London, UK) provides a crucial update on measuring relative risk of seizures following epilepsy surgery, and how this impacts on UK driving regulations. Read the paper here: http://jnnp.bmj.com/content/89/6/599

May 2018

20 min 52 sec

Patients with multiple sclerosis (MS) often show interest in complementary and alternative medicines, particularly when on long-term anti-inflammatory treatments. Is frankincense a safe and tolerable treatment? Dr Klarissa Stürner (Christian-Albrechts University, Kiel) discuss the pilot trial (conducted at the Institute of Neuroimmunology and Multiple Sclerosis, Hamburg). Read the paper here: http://jnnp.bmj.com/content/89/4/330.long Read the editorial here: http://jnnp.bmj.com/content/89/4/327

Apr 2018

16 min 55 sec

Quality of life (QoL) is one of the most important outcomes for chronic diseases, although it remains remarkably difficult to quantify. Dr. Thomas Draak (Maastricht University, The Netherlands) discusses his new questionnaire, and how it aims to capture the patient’s perspective. Read the full paper here: http://jnnp.bmj.com/content/jnnp/early/2017/11/24/jnnp-2017-316634.full.pdf

Mar 2018

8 min 8 sec

Recent research has indicated that being married is associated with a reduced risk of dementia. What is it about marriage? Dr Andrew Sommerlad (University College London) discusses this question and more. Read the full paper here: http://jnnp.bmj.com/content/early/2017/10/30/jnnp-2017-316274

Feb 2018

14 min 47 sec

Atherosclerosis is a major contributor to increased risk of stroke. Our patient’s choice, Professor Peter Kelly (University College Dublin, Dublin, Ireland) discusses the evidence base implicating inflammation as a key process in the pathogenesis of atherosclerosis, leading to thromboembolic events. Read the full paper here: http://jnnp.bmj.com/content/89/2/211. How do you measure disease progression in a highly variable and heterogeneous clinical population, such as amyotrophic lateral sclerosis (ALS)? Can plasma creatinine act as a robust surrogate biomarker in clinical trials? Dr. Ruben P A van Eijk (University Medical Center, Utrecht, The Netherlands) discusses this month’s editor’s choice. Read the full paper here: http://jnnp.bmj.com/content/89/2/156.

Feb 2018

30 min 59 sec